← Back to headlines
Sarepta Stock Declines Despite Q1 Earnings Beat, 2026 Guidance Maintained
Sarepta Therapeutics' stock turned negative despite the company reporting better-than-expected first-quarter earnings, while its 2026 guidance remains unchanged.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
